Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ for Fatigue in Multiple Sclerosis
NCT04267926Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Apr 2020
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitoquinone in multiple sclerosis (MS) (3 arms), sponsored by VA Office of Research & Development. Primary endpoint: Modified Fatigue Impact Scale at 13 weeks. Started Apr 2020; status: completed.
02
Drugs
mitoquinone
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04267926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267926.